Doug Zurawski, PharmD

A controlled substances diversion prevention program (CSDPP) that aligns with the revised ASHP guidelines is critical to ensure patients are protected from occurrences of drug diversion.

The pharmaceutical industry is already seeing the immense benefit of AI and machine-learning technology.